share_log

3D MEDICINES:自願性公告 有關美國藥監局(FDA)批准公司開展作為一線治療的錯配修復完整(pMMR)晚期或複發性子宮內膜癌患者的III期臨床研究

3D MEDICINES: VOLUNTARY ANNOUNCEMENT APPROVAL FROM FDA TO PROCEED WITH A GLOBAL PHASE III TRIAL FOR TREATMENT OF THE FIRST LINE MISMATCH REPAIR PROFICIENT (pMMR) ADVANCED OR RECURRENT ENDOMETRIAL CANCER

香港交易所 ·  Oct 29, 2023 20:29
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more